Olympus’ internal emails reveal the company told U.S. executives not to issue a broad warning to hospitals regarding a deadly infection from tainted scopes that was later linked to numerous deaths at major hospitals.
Exact Sciences’ second quarter revenue totaled $21.2 million, a 161 percent increase from revenues of $8.1 million in the second quarter of 2015.
Biomerica added Edward W. Barnholt to its newly formed strategic advisory board and Anthony J. Lembo, MD, to its scientific advisory board.
LifeBond received FDA Investigational Device Exemption approval to begin a clinical study of the LifeSeal Surgical Sealant Kit, which includes a gastrointestinal sealant.
Michael Phalen, executive vice president and group president at Boston Scientific, sold 35,000 shares of the company.
More articles on GI/endoscopy:
Surveillance endoscopy improves esophageal cancer outcomes in Barrett’s esophagus patients: 3 insights
Small bowel resection inpatient costs total $28.5k & 7 more statistics
Dr. Maxime Mahe wins 2016 AGA-Athena Troxel Blackburn Award: 4 notes
